Treatment of Hypopituitarism in a Pregnant Woman

Hypopituitarism during pregnancy requires careful hormonal management adjusted for the physiological demands of gestation. With appropriate replacement, women with hypopituitarism can expect an uneventful pregnancy and a healthy infant.

Clinical Scenario This protocol addresses the pregnant woman with established hypopituitarism — a population requiring pregnancy-specific modifications to standard hormonal replacement strategies across multiple pituitary axes.

Treatment Approach (Partial Summary) Management centres on glucocorticoid replacement, with the choice of agent guided by placental metabolism considerations specific to pregnancy. Thyroid hormone replacement and, where pre-existing conditions require it, additional hormonal management also form part of the approach — with adjustments made as gestation advances. The complete regimen, including guidance for labor and delivery, is in the full protocol.

Treatment Goals Serum fT4 or total T4 levels maintained within pregnancy target ranges, monitored every 4–6 weeks.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2016-2118

However, with appropriate hormonal replacement, women with hypopituitarism can expect an uneventful pregnancy and a healthy infant.

We suggest using HC as the preferred GC in pregnancy and increasing the dose based on the individual clinical course; higher doses may be required, in particular during the third trimester.

We recommend HC stress dosing during the active phase of labor, similar to that used in major surgical stress.

During labor and delivery, clinicians should administer a stress dose of GC (50 mg iv HC in the second stage of labor).

For cesarean section, we recommend a dose of 100 mg every 6–8 hours.

We recommend that clinicians monitor fT4 or total T4 levels every 4–6 weeks for women with CH who become pregnant and that these women may require increased L-T4 doses to maintain levels within target ranges for pregnancy.

In pregnant women with pre-existing DI, we suggest continuing DDAVP during pregnancy and adjusting doses if required.

View source ↗